SGLT2i
27 1 月, 2021 / By 王介立醫師
Sotagliflozin
仿單 [EU-202010]
[SCORED] N=10,548 (A1C>7%, eGFR 25-60, ⊕CV risk), 200→400mg/d vs placebo, 1º outcome (MACE/CV death/HF住院) HR 0.74 (0.63-0.88) at median 14m [Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. NEJM 2021]
[SOLOIST-WHF] N=1,222 (T2D+recent HF住院, A1C=7.1%, eGFR>30 [median 50], LVEF 35%), 200→400mg/d vs placebo, 1º outcome (CV death/住院, HF urgent visit) HR=0.67 (0.52-0.85) at median 9m [Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. NEJM 2021]
Ertugliflozin
仿單 [TW-201808]
[VERTIS CV] [Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. NEJM 2020]
Dapagliflozin
仿單 [TW-202011]
[DAPA-CKD] [Dapagliflozin in Patients with Chronic Kidney Disease. NEJM 2020]
[DECLARE-TIMI 58] [Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. NEJM 2019]
Canagliflozin
仿單 [TW-201905]
[CREDENCE] [Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. NEJM 2019]
[CANVAS] [Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. NEJM 2017]
Empagliflozin
仿單 [TW-202004]
[EMPEROR-Reduced] [Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. NEJM 2020]
[EMPA-REG OUTCOME] [Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. NEJM 2016]
[EMPA-REG OUTCOME] [Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. NEJM 2015]
